The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
Background: There is no single definitive test to identify prostate cancer in men. Biopsies are commonly used to obtain samples of prostate tissue for histopathological examination. However, this approach frequently misses cases of cancer, meaning that repeat biopsies may be necessary to obtain a di...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
NIHR Journals Library
2015-10-01
|
| Series: | Health Technology Assessment |
| Subjects: | |
| Online Access: | https://doi.org/10.3310/hta19870 |
| _version_ | 1818477975828430848 |
|---|---|
| author | Amanda Nicholson James Mahon Angela Boland Sophie Beale Kerry Dwan Nigel Fleeman Juliet Hockenhull Yenal Dundar |
| author_facet | Amanda Nicholson James Mahon Angela Boland Sophie Beale Kerry Dwan Nigel Fleeman Juliet Hockenhull Yenal Dundar |
| author_sort | Amanda Nicholson |
| collection | DOAJ |
| description | Background: There is no single definitive test to identify prostate cancer in men. Biopsies are commonly used to obtain samples of prostate tissue for histopathological examination. However, this approach frequently misses cases of cancer, meaning that repeat biopsies may be necessary to obtain a diagnosis. The PROGENSA® prostate cancer antigen 3 (PCA3) assay (Hologic Gen-Probe, Marlborough, MA, USA) and the Prostate Health Index (phi; Beckman Coulter Inc., Brea, CA, USA) are two new tests (a urine test and a blood test, respectively) that are designed to be used to help clinicians decide whether or not to recommend a repeat biopsy. Objective: To evaluate the clinical effectiveness and cost-effectiveness of the PCA3 assay and the phi in the diagnosis of prostate cancer. Data sources: Multiple publication databases and trial registers were searched in May 2014 (from 2000 to May 2014), including MEDLINE, EMBASE, The Cochrane Library, ISI Web of Science, Medion, Aggressive Research Intelligence Facility database, ClinicalTrials.gov, International Standard Randomised Controlled Trial Number Register and World Health Organization International Clinical Trials Registry Platform. Review methods: The assessment of clinical effectiveness involved three separate systematic reviews, namely reviews of the analytical validity, the clinical validity of these tests and the clinical utility of these tests. The assessment of cost-effectiveness comprised a systematic review of full economic evaluations and the development of a de novo economic model. Setting: The perspective of the evaluation was the NHS in England and Wales. Participants: Men suspected of having prostate cancer for whom the results of an initial prostate biopsy were negative or equivocal. Interventions: The use of the PCA3 score or phi in combination with existing tests (including histopathology results, prostate-specific antigen level and digital rectal examination), multiparametric magnetic resonance imaging and clinical judgement. Results: In addition to documents published by the manufacturers, six studies were identified for inclusion in the analytical validity review. The review identified issues concerning the precision of the PCA3 assay measurements. It also highlighted issues relating to the storage requirements and stability of samples intended for analysis using the phi assay. Fifteen studies met the inclusion criteria for the clinical validity review. These studies reported results for 10 different clinical comparisons. There was insufficient evidence to enable the identification of appropriate test threshold values for use in a clinical setting. In addition, the implications of adding either the PCA3 assay or the phi to clinical assessment were not clear. Furthermore, the addition of the PCA3 assay or the phi to clinical assessment plus magnetic resonance imaging was not found to improve discrimination. No published papers met the inclusion criteria for either the clinical utility review or the cost-effectiveness review. The results from the cost-effectiveness analyses indicated that using either the PCA3 assay or the phi in the NHS was not cost-effective. Limitations: The main limitations of the systematic review of clinical validity are that the review conclusions are over-reliant on findings from one study, the descriptions of clinical assessment vary widely within reviewed studies and many of the reported results for the clinical validity outcomes do not include either standard errors or confidence intervals. Conclusions: The clinical benefit of using the PCA3 assay or the phi in combination with existing tests, scans and clinical judgement has not yet been confirmed. The results from the cost-effectiveness analyses indicate that the use of these tests in the NHS would not be cost-effective. Study registration: This study is registered as PROSPERO CRD42014009595. Funding: The National Institute for Health Research Health Technology Assessment programme. |
| first_indexed | 2024-12-10T09:42:52Z |
| format | Article |
| id | doaj.art-286d54a9a44b401cab0c4ec1b667c174 |
| institution | Directory Open Access Journal |
| issn | 1366-5278 2046-4924 |
| language | English |
| last_indexed | 2024-12-10T09:42:52Z |
| publishDate | 2015-10-01 |
| publisher | NIHR Journals Library |
| record_format | Article |
| series | Health Technology Assessment |
| spelling | doaj.art-286d54a9a44b401cab0c4ec1b667c1742022-12-22T01:53:56ZengNIHR Journals LibraryHealth Technology Assessment1366-52782046-49242015-10-01198710.3310/hta1987014/03/01The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluationAmanda Nicholson0James Mahon1Angela Boland2Sophie Beale3Kerry Dwan4Nigel Fleeman5Juliet Hockenhull6Yenal Dundar7Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UKLiverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UKLiverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UKLiverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UKLiverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UKLiverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UKLiverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UKLiverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UKBackground: There is no single definitive test to identify prostate cancer in men. Biopsies are commonly used to obtain samples of prostate tissue for histopathological examination. However, this approach frequently misses cases of cancer, meaning that repeat biopsies may be necessary to obtain a diagnosis. The PROGENSA® prostate cancer antigen 3 (PCA3) assay (Hologic Gen-Probe, Marlborough, MA, USA) and the Prostate Health Index (phi; Beckman Coulter Inc., Brea, CA, USA) are two new tests (a urine test and a blood test, respectively) that are designed to be used to help clinicians decide whether or not to recommend a repeat biopsy. Objective: To evaluate the clinical effectiveness and cost-effectiveness of the PCA3 assay and the phi in the diagnosis of prostate cancer. Data sources: Multiple publication databases and trial registers were searched in May 2014 (from 2000 to May 2014), including MEDLINE, EMBASE, The Cochrane Library, ISI Web of Science, Medion, Aggressive Research Intelligence Facility database, ClinicalTrials.gov, International Standard Randomised Controlled Trial Number Register and World Health Organization International Clinical Trials Registry Platform. Review methods: The assessment of clinical effectiveness involved three separate systematic reviews, namely reviews of the analytical validity, the clinical validity of these tests and the clinical utility of these tests. The assessment of cost-effectiveness comprised a systematic review of full economic evaluations and the development of a de novo economic model. Setting: The perspective of the evaluation was the NHS in England and Wales. Participants: Men suspected of having prostate cancer for whom the results of an initial prostate biopsy were negative or equivocal. Interventions: The use of the PCA3 score or phi in combination with existing tests (including histopathology results, prostate-specific antigen level and digital rectal examination), multiparametric magnetic resonance imaging and clinical judgement. Results: In addition to documents published by the manufacturers, six studies were identified for inclusion in the analytical validity review. The review identified issues concerning the precision of the PCA3 assay measurements. It also highlighted issues relating to the storage requirements and stability of samples intended for analysis using the phi assay. Fifteen studies met the inclusion criteria for the clinical validity review. These studies reported results for 10 different clinical comparisons. There was insufficient evidence to enable the identification of appropriate test threshold values for use in a clinical setting. In addition, the implications of adding either the PCA3 assay or the phi to clinical assessment were not clear. Furthermore, the addition of the PCA3 assay or the phi to clinical assessment plus magnetic resonance imaging was not found to improve discrimination. No published papers met the inclusion criteria for either the clinical utility review or the cost-effectiveness review. The results from the cost-effectiveness analyses indicated that using either the PCA3 assay or the phi in the NHS was not cost-effective. Limitations: The main limitations of the systematic review of clinical validity are that the review conclusions are over-reliant on findings from one study, the descriptions of clinical assessment vary widely within reviewed studies and many of the reported results for the clinical validity outcomes do not include either standard errors or confidence intervals. Conclusions: The clinical benefit of using the PCA3 assay or the phi in combination with existing tests, scans and clinical judgement has not yet been confirmed. The results from the cost-effectiveness analyses indicate that the use of these tests in the NHS would not be cost-effective. Study registration: This study is registered as PROSPERO CRD42014009595. Funding: The National Institute for Health Research Health Technology Assessment programme.https://doi.org/10.3310/hta19870clinical effectivenesscost-effectivenessprogensa pca3 assayprostate health indexphidiagnosisprostate cancersystematic revieweconomic evaluation |
| spellingShingle | Amanda Nicholson James Mahon Angela Boland Sophie Beale Kerry Dwan Nigel Fleeman Juliet Hockenhull Yenal Dundar The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation Health Technology Assessment clinical effectiveness cost-effectiveness progensa pca3 assay prostate health index phi diagnosis prostate cancer systematic review economic evaluation |
| title | The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation |
| title_full | The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation |
| title_fullStr | The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation |
| title_full_unstemmed | The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation |
| title_short | The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation |
| title_sort | clinical effectiveness and cost effectiveness of the progensa r prostate cancer antigen 3 assay and the prostate health index in the diagnosis of prostate cancer a systematic review and economic evaluation |
| topic | clinical effectiveness cost-effectiveness progensa pca3 assay prostate health index phi diagnosis prostate cancer systematic review economic evaluation |
| url | https://doi.org/10.3310/hta19870 |
| work_keys_str_mv | AT amandanicholson theclinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT jamesmahon theclinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT angelaboland theclinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT sophiebeale theclinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT kerrydwan theclinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT nigelfleeman theclinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT juliethockenhull theclinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT yenaldundar theclinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT amandanicholson clinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT jamesmahon clinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT angelaboland clinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT sophiebeale clinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT kerrydwan clinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT nigelfleeman clinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT juliethockenhull clinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation AT yenaldundar clinicaleffectivenessandcosteffectivenessoftheprogensaprostatecancerantigen3assayandtheprostatehealthindexinthediagnosisofprostatecancerasystematicreviewandeconomicevaluation |